Glucagon-like peptide-1, or GLP-1, receptor agonists have transformed the way medicine approaches weight management and metabolic health. Medications such as Semaglutide, Tirzepatide, and Liraglutide are now widely prescribed for obesity, insulin resistance, and type 2 diabetes, offering patients effective tools to achieve significant weight reduction. As these therapies have become more popular, aesthetic providers have begun observing predictable changes in the skin that often accompany rapid or substantial weight loss. While GLP-1 medications do not directly age the skin, the physiological consequences of fat reduction, caloric restriction, and metabolic shifts can influence facial contours, overall skin laxity, and hair quality, making a nuanced understanding of these effects increasingly important for those in aesthetic practice.
One of the most talked-about changes associated with GLP-1 therapy is facial volume loss, sometimes colloquially referred to as “Ozempic face.” This is not a side effect unique to any specific medication but rather a natural outcome of accelerated fat depletion. Patients may notice hollowing in the midface, more prominent nasolabial folds, skeletal definition around the eyes, and laxity in the lower face and jawline. Rapid loss of both superficial and deep facial fat diminishes structural support, and in patients over forty—or those with preexisting collagen decline or photodamage—the skin may not contract proportionally, subtly amplifying signs of aging. Addressing these changes requires a careful, thoughtful approach. Rather than simply adding volume indiscriminately, aesthetic providers often focus on restoring structural support through conservative hyaluronic acid filler placement, collagen-stimulating biostimulators, and energy-based skin tightening treatments, typically delivered in staged sessions to ensure a harmonious, natural result.
Weight loss associated with GLP-1 therapy can also reveal laxity in other areas of the body, particularly the abdomen, upper arms, inner thighs, and submental region. The degree of skin redundancy is influenced by age, the duration of previous obesity, genetic collagen integrity, photodamage, and the speed of weight loss. Non-surgical treatments, including radiofrequency microneedling, fractional laser resurfacing, ultrasound-based tightening, and collagen-induction therapies, can help improve texture and firmness, while surgical consultation may be warranted in cases of more pronounced sagging.
A particularly compelling option for patients seeking non-surgical correction is Ellacor microcoring. This minimally invasive procedure removes tiny sections of skin to reduce sagging while simultaneously stimulating collagen production, resulting in smoother, tighter, and more resilient skin. For individuals experiencing the predictable skin changes associated with GLP-1 therapy, Ellacor offers an elegant, targeted solution that addresses both texture and laxity, complementing other aesthetic interventions.
As GLP-1 medications continue to redefine metabolic medicine and weight management, aesthetic providers are increasingly positioned to guide patients through the accompanying transformations in skin appearance. By understanding the interplay between facial volume loss, body laxity, and innovative treatments such as Ellacor, providers can offer sophisticated, patient-centered care that not only enhances natural beauty but also supports confidence and well-being throughout the journey of weight change.
Shani Caviness, PA-C , ELYSIAN Beauty Subject Matter Expert